SystImmune and Bristol Myers Squibb announce interim Phase III data showing Iza-bren significantly improves outcomes in previously treated triple-negative breast cancer (TNBC) patients.
SystImmune, Inc. and Bristol Myers Squibb have announced positive topline results from a pivotal Phase III clinical trial evaluating izalontamab brengitecan (iza-bren), a next-generation bispecific antibody-drug conjugate (ADC), in patients with previously treated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The results, reported by SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd., mark a significant milestone in the development of bispecific ADC technology and highlight the growing global collaboration aimed at advancing innovative cancer therapeutics.
Positive Phase III Interim Results in Advanced TNBC
The findings come from a pre-specified interim analysis of the Phase III BL-B01D1-307 study, which evaluated iza-bren in patients whose disease had progressed following prior taxane-based chemotherapy. Triple-negative breast cancer is one of the most aggressive and difficult-to-treat subtypes of breast cancer, characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. Patients with advanced TNBC often face limited therapeutic options and poor prognoses once standard treatments fail.
In the interim analysis, iza-bren demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared with chemotherapy of physician’s choice. Importantly, the study met its dual primary endpoints of PFS and OS, underscoring the strength of the treatment effect. These results suggest that iza-bren may offer a new standard-of-care option for patients with advanced TNBC who have exhausted first-line therapies.
This trial represents the third Phase III study in which iza-bren has successfully achieved its primary endpoint or endpoints. Notably, it is also the first bispecific ADC to report dual positive PFS and OS results in a Phase III study specifically in triple-negative breast cancer, setting a new benchmark for this emerging therapeutic class.
Innovative Mechanism: EGFR×HER3 Bispecific ADC
Izalontamab brengitecan is designed as a bispecific antibody-drug conjugate targeting both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). These receptors are frequently overexpressed or dysregulated in various solid tumors, including TNBC, and are associated with tumor growth, survival, and resistance mechanisms.
By simultaneously targeting EGFR and HER3, iza-bren aims to enhance tumor selectivity and therapeutic potency. The ADC component delivers a cytotoxic payload directly to cancer cells, potentially improving efficacy while limiting systemic toxicity. The bispecific design may also overcome resistance pathways that limit the effectiveness of single-target therapies.
The dual-target approach is increasingly viewed as a promising strategy in oncology drug development, particularly in hard-to-treat cancers where signaling redundancy contributes to treatment resistance. The positive data from BL-B01D1-307 reinforce the potential of bispecific ADCs as a transformative platform in cancer therapeutics.
Leadership Commentary
Dr. Yi Zhu, Chief Executive Officer of Biokin, emphasized the urgent unmet medical need in advanced TNBC, noting that patients who progress after standard therapies often have few effective treatment options. He stated that the topline results strengthen confidence in iza-bren’s potential to deliver meaningful clinical benefit across multiple cancer indications.
Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, highlighted the broader implications of the findings. He underscored the promise of bispecific ADC technology targeting both EGFR and HER3, suggesting that such approaches could meaningfully change outcomes in difficult-to-treat cancers. He also reiterated the company’s commitment to advancing ADC science to uncover new treatment options for patients living with cancer.
Global Collaboration and Development Strategy
The BL-B01D1-307 study is sponsored by Biokin in Mainland China. Outside of China, iza-bren is being jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement. This partnership reflects a growing trend of cross-border collaboration in oncology drug development, combining regional clinical expertise with global commercialization capabilities.
Such collaborations enable accelerated development timelines, broader geographic trial enrollment, and coordinated regulatory strategies. For iza-bren, the joint effort positions the therapy for potential global regulatory submissions and commercialization, pending final data and regulatory review.
Regulatory Momentum in China and the United States
Izalontamab brengitecan has already received significant regulatory recognition in multiple jurisdictions. The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to iza-bren for seven indications, reflecting its potential to address serious conditions with substantial improvement over existing therapies.
In addition, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to iza-bren for previously treated non-small cell lung cancer (NSCLC) patients with an EGFR mutation. This designation is intended to expedite the development and review of drugs that demonstrate substantial improvement over available treatments.
Further regulatory progress has been made in China, where New Drug Applications (NDAs) for two indications—locally advanced or metastatic nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma—have been accepted by the CDE and included in the priority review process. These developments indicate that iza-bren’s clinical activity may extend beyond breast cancer, potentially positioning it as a multi-indication oncology therapy.
Broader Implications for TNBC Treatment
Triple-negative breast cancer remains an area of intense research focus due to its aggressive nature and lack of targeted therapies. While immunotherapy and antibody-drug conjugates have expanded treatment options in recent years, many patients still experience disease progression after standard regimens.
The demonstration of dual improvement in both PFS and OS is particularly noteworthy. While progression-free survival often serves as an early indicator of clinical benefit, overall survival remains the gold standard endpoint in oncology trials. Achieving statistically significant improvements in both measures strengthens the clinical relevance of the findings and may support future regulatory filings.
If confirmed in the final analysis and subsequent peer-reviewed presentations, these results could significantly influence treatment guidelines and reshape the therapeutic landscape for previously treated advanced TNBC.
Next Steps
The data from the BL-B01D1-307 study are expected to be presented at an upcoming medical meeting, where more detailed efficacy and safety results will likely be shared. Such presentations will provide clinicians and researchers with deeper insights into response rates, duration of response, safety profiles, and subgroup analyses.
As development progresses, regulatory submissions in multiple regions may follow, supported by the positive interim results and existing Breakthrough Therapy Designations. The continued collaboration between SystImmune, Biokin, and Bristol Myers Squibb will be critical in advancing iza-bren through the next stages of global development.
